Patent · US Active

Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates

US7723485B2 · kind B2 · utility

132Cited by
4References
40Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 7, 2008
Grant dateMay 25, 2010
Priority date—
Expiry dateMay 7, 2028

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/55
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I:Ab-(L-D)p  I

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.